Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981641 | 0.81 | NOTUM (0.60) | MAPTHTTALDH1A1SMN1; SMN2DRD2 | |
| SCHEMBL3585115 | 0.79 | NOTUM (0.56) | MAPTHTTALDH1A1SMN1; SMN2DRD2 | |
| SCHEMBL30575716 | 0.79 | NOTUM (0.56) | MAPTHTTALDH1A1SMN1; SMN2DRD2 | |
| SCHEMBL399528 | 0.78 | NOTUM (0.51) | MAPTHTTALDH1A1SMN1; SMN2DRD2 | |
| SCHEMBL28360647 | 0.74 | NOTUM (0.56) | MAPTKDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL27999083 | 0.73 | MAPT (0.44) | MAPTKDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL27872558 | 0.73 | DRD2 (0.57) | MAPTHTTALDH1A1SMN1; SMN2DRD2 | |
| SCHEMBL5144014 | 0.72 | KDM4E (0.58) | MAPTKDM4EHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL3735431 | 0.72 | DRD2 (0.56) | MAPTHTTALDH1A1SMN1; SMN2DRD2 | |
| SCHEMBL5798736 | 0.71 | MAPT (0.67) | MAPTKDM4EHTTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MAPT 4269/4885KDM4E 4262/4885HTT 1579/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | MAPT 4269/4885KDM4E 4262/4885HTT 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.